Skip to main content
Premium Trial:

Request an Annual Quote

Luminex Shares Climb 20 Percent

Shares of Luminex rose 20 percent for the five-day trading period ended Tuesday. The firm did not report any news or US Securities and Exchange Commission filings since it reported second-quarter results two weeks ago.
 
Luminex led all gainers in the BCW Index for the week. Affymetrix also posted a double-digit gain with shares rising 12.6 percent. Shares of Millipore, which reported a slight dip in second-quarter profits last week (see Briefs), fell 4.9 percent for the tracking period to lead decliners.
 

Overall, the Index rose 3.5 percent for the week. The Dow Jones Industrial Average rose 2.2 percent, the Nasdaq was up .6 percent, and the Nasdaq Biotech Index gained 2.5 percent.

 
 
BioCommerce Week Index of Diversified
Molecular Biology Tool Companies
Company
Ticker
Closing Price
(Aug. 7, 2007)
Starting Price
(July 31, 2007)
% change
Affymetrix
AFFX
27.45
24.38
12.59
Agilent
A
38.3
38.15
0.39
Applied Biosystems
ABI
32.54
31.22
4.23
Beckman
BEC
71.46
70.82
0.90
Becton Dickinson
BDX
77.6
76.36
1.62
Bio-Rad
BIO
77.16
74.16
4.05
Bruker
BRKR
7.46
7.83
-4.73
Caliper
CALP
5.05
4.8
5.21
Cepheid
CPHD
15.56
14.75
5.49
Illumina
ILMN
49.44
45.57
8.49
Invitrogen
IVGN
78.8
71.8
9.75
Luminex
LMNX
14.4
11.94
20.60
MDS
MDZ
19.0
19.09
-0.47
Millipore
MIL
74.78
78.61
-4.87
PerkinElmer
PKI
27.03
27.83
-2.87
Qiagen
QGEN
17.98
17.2
4.53
Sequenom
SQNM
5.35
5.31
0.75
Sigma-Aldrich
SIAL
48.21
45.32
6.38
Thermo
TMO
52.1
52.21
-0.21
Third Wave
TWTI
7.23
7.29
-0.82
Waters
WAT
63.31
58.26
8.67
BCW Index Average  
38.58
37.28
3.49
The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.